Moleculin Biotech (Nasdaq:MBRX) - Cotización, noticias y análisis

Resumen de acción MBRX

Moleculin Biotech, Inc. es una empresa farmacéutica en fase clínica centrada en el desarrollo de fármacos candidatos para el tratamiento de cánceres y virus.

Acerca de la empresa

MBRX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene menos de 1 año de cash runway

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 2 riesgos adicionales

Competidores de Moleculin Biotech, Inc.

Molecular Templates

NasdaqCM:MTEM

US$7.9m

Bionomics

NasdaqGM:BNOX

US$10.5m

Virios Therapeutics

NasdaqCM:VIRI

US$8.4m

Applied Molecular Transport

NasdaqCM:AMTI

US$10.9m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Moleculin Biotech
Historical stock prices
Current Share Price	US$4.65
52 Week High	US$15.75
52 Week Low	US$4.28
Beta	1.85
1 Month Change	-29.86%
3 Month Change	-43.32%
1 Year Change	-60.41%
3 Year Change	-91.14%
5 Year Change	-96.36%
Change since IPO	-99.35%

Noticias y actualizaciones recientes

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jan 15

Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas

Dec 29

Moleculin Bio on go with mid-stage study of Annamycin for lung metastases

Dec 17

Moleculin Biotech's annamycin shows encouraging action in animal study

Nov 19

Moleculin Biotech EPS beats by $0.04

Nov 13

Moleculin further collaborates to advance WP1122 in COVID-19

Oct 29

Rentabilidad de los accionistas

	MBRX	US Biotechs	Mercado US
7D	0.5%	-2.5%	-3.2%
1Y	-60.4%	-3.7%	19.3%

Rentabilidad vs. Industria: MBRX obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 11.6%.

Rentabilidad vs. Mercado: MBRX obtuvo unos resultados inferiores a los del mercado US, que fue del 31.1% el año pasado.

Volatilidad de los precios

Is MBRX's price volatile compared to industry and market?
MBRX volatility
MBRX Average Weekly Movement	14.0%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: MBRXha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: MBRX(14%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2015	18	Wally Klemp	moleculin.com

Moleculin Biotech, Inc. es una empresa farmacéutica en fase clínica centrada en el desarrollo de fármacos candidatos para el tratamiento de cánceres y virus. Su principal candidato a fármaco es la annamicina, que se encuentra en estudios de fase 1/2 para el tratamiento de la leucemia mieloide aguda (LMA) recidivante o refractaria y de cánceres con metástasis en los pulmones. El modulador inmunitario/de transcripción estrella de la empresa es WP1066, que se encuentra en ensayos clínicos de fase I para el tratamiento de tumores cerebrales y tumores cerebrales pediátricos, así como cáncer de páncreas y otras neoplasias malignas.

Resumen de fundamentos de Moleculin Biotech, Inc.

¿Cómo se comparan los beneficios e ingresos de Moleculin Biotech con su capitalización de mercado?
Estadísticas fundamentales de MBRX
Capitalización bursátil	US$10.36m
Beneficios(TTM)	-US$29.77m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.3x

Ratio precio-beneficio (PE)

¿Está MBRX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MBRX
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$29.77m
Beneficios	-US$29.77m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-13.36
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado MBRX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción MBRX

Recompensas

Análisis de riesgos

Competidores de Moleculin Biotech, Inc.

NasdaqCM:MTEM

US$7.9m

NasdaqGM:BNOX

US$10.5m

NasdaqCM:VIRI

US$8.4m

NasdaqCM:AMTI

US$10.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

New major risk - Share price stability

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Recent updates

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

New major risk - Share price stability

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

New major risk - Share price stability

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Price target decreased to US$8.67

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Price target decreased to US$11.67

Price target increased to US$21.50

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Moleculin Biotech, Inc. Receives IND Clearance to Conduct Phase 1 Study of WP1066 for Treatment of Recurrent Malignant Glioma

Moleculin Biotech, Inc., Annual General Meeting, May 26, 2022

Moleculin Biotech, Inc. Announces Presentation of Positive Preclinical Annamycin Data At the AACR 2022 Annual Meeting

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth

Moleculin Biotech, Inc. Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

Price target increased to US$23.50

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

Moleculin Biotech, Inc. Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Moleculin Biotech, Inc. Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme